汉康生技四项科学摘要
获ESMO 2026大会接收
彰显差异化免疫治疗策略
HCB101的工程化巨噬细胞激活机制及不断积累的临床证据支持其作为联合治疗基石的潜力;HCB301则体现汉康生技FBDB™平台的多特异性工程能力
【台北、上海、旧金山 | 2026年10月28日】— 汉康生技股份有限公司(TWSE:7827)是一家致力于开发用于肿瘤及免疫介导疾病下一代免疫疗法的全球临床阶段生物技术公司。公司今日宣布,涵盖HCB101和HCB301的四项科学摘要已获ESMO 2026大会接收。该大会于10月23日至27日在西班牙马德里举行。
相关研究体现了汉康生技超越单一通路免疫检查点阻断的免疫治疗策略,即将巨噬细胞介导的肿瘤清除与成熟及新兴肿瘤治疗方案相结合。
HCB101:超越CD47阻断
专为联合治疗而设计
HCB101是一款工程化SIRPα–IgG4 Fc融合蛋白,旨在阻断CD47–SIRPα先天免疫检查点,同时最大限度降低与红细胞的结合。
不同于采用效应功能沉默型IgG1 Fc的CD47抑制剂,HCB101凭借含功能性IgG4 Fc的分子结构,保留了巨噬细胞介导的吞噬活性。已发表的临床前研究显示,HCB101可诱导强效的肿瘤细胞吞噬,同时仅引起极低水平的红细胞吞噬。
这一功能差异为HCB101与无法提供强效Fc介导肿瘤调理作用的疗法联合使用提供了科学依据,包括PD-1抑制剂、化疗、抗血管生成药物以及HER2/EGFR靶向抗体。
不断积累的临床证据支持进一步评估这一策略。HCB101单药治疗显示出持续的CD47受体占有,并在头颈癌中取得经确认的部分缓解,患者持续接受治疗已超过83周。在二线胃癌/胃食管结合部癌(GC/GEJ)中,HCB101联合雷莫西尤单抗和紫杉醇取得初步50.0%的客观缓解率(ORR,11/22)和100%的疾病控制率(DCR,22/22)。此外,在一线HER2阳性胃癌中观察到77.8%的ORR(7/9),在二线结直肠癌中观察到35.3%的ORR(6/17)。
这些早期、非随机临床结果支持继续评估HCB101与不同治疗基石方案的联合应用,但仍需通过对照研究确定其增量治疗贡献。二线GC/GEJ仍是汉康生技临床开发的首要重点。
从临床证据迈向合作驱动的创新
基于上述临床基础,汉康生技正在探索新一代联合治疗方案,包括PD-1/VEGF双特异性抗体、抗体偶联药物(ADC)、治疗性肿瘤疫苗,以及靶向互补性肿瘤微环境通路的小分子药物。
公司的合作策略包括与应世生物围绕FAK抑制剂IN10018开展合作,以及近期与Aston Sci签署涉及治疗性肿瘤疫苗的谅解备忘录。
这些举措体现了汉康生技将HCB101开发为多用途、巨噬细胞导向型联合治疗基石的目标,使其有望与公司内部研发管线之外的治疗创新形成互补。
“下一代免疫治疗不能仅仅解除抑制性免疫检查点,还必须调动能够协同发挥作用的互补性免疫机制。”汉康生技创始人、董事长兼首席执行官刘世高博士表示,“我们通过工程化设计,使HCB101超越CD47阻断,在最大限度减少红细胞相互作用的同时,支持巨噬细胞介导的肿瘤清除。不断积累的临床证据支持HCB101与多种疗法联合开发,涵盖现有标准治疗、双特异性抗体、ADC及肿瘤疫苗。依托FBDB™平台及不断拓展的合作,我们致力于将这一差异化生物学机制转化为更广泛的治疗机会。”
FBDB™:通过多特异性工程
拓展先天免疫
汉康生技专有的Fc-Based Designer Biologics(FBDB™)平台结合蛋白质工程、Fc功能优化及多特异性分子设计,开发针对互补性免疫机制的治疗方案。
HCB301体现了这一理念。该三特异性融合蛋白将SIRPα、PD-L1和TGFβ通路调节整合于单一分子中,旨在同时应对先天免疫抑制、适应性免疫检查点耐药及肿瘤微环境调控。
一项展示HCB301 I期研究早期结果的科学海报将由研究者在ESMO 2026大会上进行报告。该研究的临床安全性结果及治疗窗仍需进一步评估。
ESMO 2026大会科学摘要
HCB101 三项获接收的电子海报摘要
HCB101联合雷莫西尤单抗和紫杉醇治疗二线晚期胃癌:一项Ib/IIa期试验结果
HCB101作为跨消化道肿瘤的先天免疫治疗基石:胃癌临床验证及向结直肠癌的早期拓展
HCB101作为PD-1联合治疗的先天免疫治疗基石:在头颈部鳞状细胞癌和三阴性乳腺癌中的早期临床信号
HCB301 科学海报报告
HCB301-101:三功能SIRPα/PD-L1/TGF-β生物制剂治疗晚期实体瘤的I期研究早期安全性与疾病控制结果
四项摘要均已收到接收通知。大会最终科学议程将收录HCB301研究,三项HCB101电子海报则不会纳入最终科学议程。
关于汉康生技
汉康生技(TWSE:7827)是一家全球临床阶段生物技术公司,依托专有FBDB™平台,致力于开发用于肿瘤及免疫介导疾病的下一代生物制剂。基于多功能蛋白质工程技术,公司研发管线包括HCB101、HCB301和HCB303。汉康生技在台北、旧金山湾区及上海开展业务,致力于重塑免疫疗法,为全球患者带来新的治疗选择。
更多信息请访问:
www.HanchorBio.com。
前瞻性声明
本新闻稿包含有关汉康生技在研产品、平台技术、潜在治疗应用、临床开发、联合治疗策略及战略合作的前瞻性声明。
该等声明涉及科学、临床、监管、运营及商业风险和不确定性。初步临床及临床前结果未必能够预测后续研究结果。汉康生技在研产品及拟议联合治疗的安全性、有效性和增量治疗贡献尚未在充分对照的临床试验中得到证实。未来开发活动及合作将取决于进一步研究、监管要求及适用协议。
除适用法律另有规定外,汉康生技不承担更新该等声明的义务。
汉康生技商务拓展联系人:
电子邮箱:BD@HanchorBio.com
投资者及媒体联系人:
电子邮箱:IRPR@hanchorbio.com
HanchorBio Announces Acceptance of Four Scientific Abstracts for ESMO Congress 2026, Highlighting Differentiated Immunotherapy Strategy
HCB101's engineered macrophage activation and emerging clinical evidence support its potential as a combination backbone, while HCB301 demonstrates the multi-specific engineering capabilities of HanchorBio's FBDB™ platform
TAIPEI, SHANGHAI, and SAN FRANCISCO — October 28, 2026 — HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, today announced that four scientific abstracts covering HCB101 and HCB301 were accepted for ESMO Congress 2026, taking place October 23–27 in Madrid, Spain.
The research highlights HanchorBio's strategy to advance immunotherapy beyond single-pathway checkpoint blockade by integrating macrophage-mediated tumor clearance with established and emerging cancer treatments.
HCB101: Beyond CD47 Blockade — Engineered for Combination
HCB101 is an engineered SIRPα–IgG4 Fc fusion protein designed to block the CD47–SIRPα innate immune checkpoint while minimizing red blood cell binding.
Unlike CD47 inhibitors incorporating an effector-silenced IgG1 Fc, HCB101 retains macrophage-mediated phagocytic activity through its functional IgG4 Fc-containing architecture. Published preclinical studies demonstrated robust tumor-cell phagocytosis with minimal red blood cell phagocytosis.
This functional distinction provides a scientific rationale for combining HCB101 with therapies that do not provide strong Fc-mediated tumor-opsonizing activity, including PD-1 inhibitors, chemotherapy, anti-angiogenic agents, and HER2/EGFR-directed antibodies.
Emerging clinical evidence supports further evaluation of this strategy. HCB101 monotherapy demonstrated sustained CD47 receptor occupancy and a confirmed partial response in head and neck cancer, with treatment ongoing beyond 83 weeks. In second-line gastric/gastroesophageal junction (GC/GEJ) cancer, HCB101 combined with ramucirumab and paclitaxel achieved a preliminary objective response rate (ORR) of 50.0% (11/22) and disease control rate (DCR) of 100% (22/22). Additional activity was observed in first-line HER2-positive gastric cancer (ORR 77.8%, 7/9) and second-line colorectal cancer (ORR 35.3%, 6/17).
These early, nonrandomized clinical findings support continued evaluation of HCB101 across distinct treatment backbones, with controlled studies needed to establish its incremental therapeutic contribution. Second-line GC/GEJ cancer remains HanchorBio's lead clinical development priority.
From Clinical Evidence to Partner-Enabled Innovation
Building on this clinical foundation, HanchorBio is exploring next-generation combinations involving PD-1/VEGF bispecific antibodies, antibody-drug conjugates (ADCs), therapeutic cancer vaccines, and small molecules targeting complementary tumor microenvironment pathways.
Its collaboration strategy includes InxMed's FAK inhibitor IN10018 and a recently signed memorandum of understanding with Aston Sci. involving therapeutic cancer vaccines.
These initiatives reflect HanchorBio's ambition to develop HCB101 as a versatile macrophage-directed backbone that may complement therapeutic innovation beyond its internal pipeline.
"The next generation of immunotherapy must do more than release inhibitory checkpoints. It must engage complementary immune mechanisms that can work together," said Scott Liu, PhD, Founder, Chairman, and CEO of HanchorBio. "With HCB101, we have engineered a molecule that goes beyond CD47 blockade to support macrophage-mediated tumor clearance while minimizing red blood cell interactions. Our emerging clinical evidence supports development across multiple treatment combinations, from established standards of care to bispecific antibodies, ADCs, and cancer vaccines. Through our FBDB™ platform and expanding collaborations, we aim to translate this differentiated biology into broader therapeutic opportunities."
FBDB™: Extending Innate Immunity Through Multi-Specific Engineering
HanchorBio's proprietary Fc-Based Designer Biologics (FBDB™) platform combines protein engineering, Fc-function optimization, and multi-specific molecular design to develop therapies addressing complementary immune mechanisms.
HCB301 exemplifies this approach through a trispecific fusion protein that integrates SIRPα, PD-L1, and TGFβ pathway modulation into a single molecule, designed to address innate immune suppression, adaptive checkpoint resistance, and tumor microenvironment regulation.
A scientific poster featuring early HCB301 Phase 1 findings will be presented by a study investigator at ESMO Congress 2026. The study's clinical safety findings and therapeutic window require further evaluation.
ESMO Congress 2026
— Scientific Abstracts
HCB101 — Three Accepted ePoster Abstracts
HCB101 Plus Ramucirumab and Paclitaxel in Second-line Advanced Gastric Cancer: Results From a Phase 1b/2a Trial
HCB101 as a Cross-GI Innate Immune Backbone: Clinical Validation in Gastric Cancer and Early Extension to Colorectal Cancer
HCB101 as an Innate Immune Backbone for PD-1-Based Combinations: Early Clinical Signals in HNSCC and TNBC
HCB301 — Scientific Poster Presentation
HCB301-101: Early Safety and Disease Control From a Phase 1 Study of a Tri-Functional SIRPα/PD-L1/TGF-β Biologic in Advanced Solid Tumors
All four abstracts received acceptance notifications. The congress will include the HCB301 study, while the three HCB101 ePosters will not be included in the final scientific program.
About HanchorBio
HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company developing next-generation biologics for cancer and immune-mediated diseases through its proprietary FBDB™ platform. Powered by a multifunctional protein-engineering technology, its pipeline includes HCB101, HCB301, and HCB303. Operating across Taipei, the San Francisco Bay Area, and Shanghai, HanchorBio is committed to reimagining immunotherapy for patients worldwide. For more information, visit: www.HanchorBio.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding HanchorBio's investigational products, platform technologies, potential therapeutic applications, clinical development, combination strategies, and strategic collaborations.
These statements involve scientific, clinical, regulatory, operational, and commercial risks and uncertainties. Preliminary clinical and preclinical findings may not predict outcomes in subsequent studies. The safety, efficacy, and incremental therapeutic contribution of HanchorBio's investigational products and proposed combinations have not been established in adequately controlled clinical trials. Future development activities and collaborations are subject to additional research, regulatory requirements, and applicable agreements.
Except as required by applicable law, HanchorBio undertakes no obligation to update these statements.
HanchorBio Business Development Contact:
Email: BD@HanchorBio.com
Investor & Media Contact:
Email: IRPR@hanchorbio.com